This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These might be licensed drugs that could hold potential for a patent extension, or drugs which failed efficacy trials for an intended indication. In the quest to repurpose a drug for a rare condition, there is a need to look at any and all available data. The post Rare diseases, repurposing and the role of AI appeared first on.
Licensed Clinical Psychologist, Clinical Director, Virtual Counselor/College Telehealth. Recent shifts in rep access, HCP media preferences and the emergence of new data-driven platforms have forced pharmaceutical and lifescience organizations to accelerate their digital transformation. Reena Kolar , Ph.D,
Licensed Clinical Psychologist, Clinical Director, Virtual Counselor/College Telehealth. Recent shifts in rep access, HCP media preferences and the emergence of new data-driven platforms have forced pharmaceutical and lifescience organizations to accelerate their digital transformation. Reena Kolar , Ph.D,
Meanwhile, the search for the ‘right target’ led the company to collaborate with Cancer Research UK and launch the Functional Genomics Centre , a centre of excellence for genetic screening, cancer modelling and bigdata processing aimed at accelerating the discovery of new cancer medicines, including those based on CRISPR technology.
Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. In 2022, the FDA proceeded to grant official licensing for Moderna’s Spikevax COVID-19 vaccine.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content